Filtered By:
Source: Thrombosis Research
Condition: Thrombosis
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 219 results found since Jan 2013.
Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes – A note of caution
Rivaroxaban is a direct factor Xa inhibitor currently licensed for the acute treatment and prevention of venous thromboembolism and for the prevention of stroke in the context of atrial fibrillation (AF). Rivaroxaban is rapidly absorbed with maximum concentrations reported around 2 –4 h post ingestion. Oral bioavailability is high (80–100%) for the 2.5 mg and 10 mg tablet dose under fasting conditions or with food. The 20 mg dose of rivaroxaban has reduced bioavailability of 66%, under fasting conditions, increasing to near 100% when taken with food [1, 6].
Source: Thrombosis Research - June 19, 2018 Category: Hematology Authors: Rosalind Byrne, Alison Brown, Jignesh P. Patel, Julia Czuprynska, Lara N. Roberts, Raj K. Patel, Roopen Arya Tags: Letter to the Editors-in-Chief Source Type: research
Treatment of arterial thrombosis in children: Methods and mechanisms
Arterial thrombosis is increasingly recognized in children and is mostly related to the presence of an arterial catheter or an ischemic stroke. Treatment of children with arterial thrombosis varies widely and consists on the administration of the common available anticoagulant und antiplatelet drugs. No evidence-based guidelines are available so far to prefer one treatment approach to another. Data in adults indicate that understanding the pathomechanism and composition of arterial thrombosis is crucial for choosing the most efficient and safe antithrombotic drug.
Source: Thrombosis Research - July 6, 2018 Category: Hematology Authors: Mattia Rizzi, Manuela Albisetti Tags: Review Article Source Type: research
Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study
The non-vitamin K oral antagonists (NOACs) are at least as effective as warfarin in the prevention of stroke in non valvular atrial fibrillation (NVAF) and are associated with less intracranial hemorrhage. Many patients with NVAF inappropriately do not receive anticoagulants often because of the inconvenience associated with warfarin administration. NOACs have the potential to increase anticoagulation use because they are safer and easier to administer than warfarin. Indeed, the use of anticoagulation in patients with newly diagnosed AF in many countries is increasing as a result of the use of NOACs in preference to warfarin [1].
Source: Thrombosis Research - July 24, 2018 Category: Hematology Authors: Martin H. Ellis, Sari Greenberg Dotan, Ariel Hammerman, Erez Battat, Estela Derazne, Orly Avnery Tags: Letter to the Editors-in-Chief Source Type: research
The effect of tyramine infusion and exercise on blood flow, coagulation and clot microstructure in healthy individuals
In this study we explore the relationship between catecholamine release and hemodynamic changes and their effect on coagulation.
Source: Thrombosis Research - July 26, 2018 Category: Hematology Authors: Matthew J. Lawrence, Gareth Davies, Michael Nyberg, Janet Whitley, Vanessa Evans, Rhodri Williams, Ylva Hellsten, Phillip A. Evans Tags: Full Length Article Source Type: research
9. Abstract Title: Measurement of anti-factor Xa direct oral anticoagulant levels in the plasma samples from the perioperative anticoagulant use for surgery evaluation (PAUSE) study
We report a new assay that measures anti-FXa DOAC levels in plasma and whole blood. This is achieved by measuring the rate of prothrombin cleavage by residual FXa activity, which is inversely proportional to the DOAC levels present.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Luca R. Di Giuseppantonio, Chengliang Wu, Peter L. Gross, James D. Douketis, Paul Y. Kim Source Type: research
6. Abstract Title: Thrombotic and Bleeding Outcomes Following Perioperative Interruption of DOACs and VKAs in Patients with Non-Valvular Atrial Fibrillation - A Comparative Analysis
Background: Atrial fibrillation (AF) is a common disorder that will affect up to 5.6 million patients in the U.S. by 2050. Both direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs), typically warfarin, are used for stroke prevention in AF and such patients frequently undergo invasive procedures, requiring anticoagulant interruption. Temporary interruption of anticoagulants can be associated with significant morbidity and mortality in the form of thromboembolic and bleeding complications.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Joseph Shaw, Tinghua Zhang, Gregoire Le Gal, James Douketis, Marc Carrier Source Type: research
1. Abstract Title: Management of Cerebral Vein Thrombosis in a Large Canadian Tertiary Hospital
Introduction: Cerebral vein thrombosis (CVT) is an uncommon cause of stroke and is more likely to affect young adults and children. Women have a three-fold increased risk compared to men, owing to gender specific factors such as oral contraceptive use (OCP), pregnancy, and hormone replacement therapies. The presenting symptoms of CVT are non-specific and include headache, seizure, focal neurological deficits, or coma as the most severe presentation. The rarity and variable symptoms of the disease leads to delayed diagnosis and implementation of treatment.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Lana Castellucci, Philip Chiang Source Type: research
Apixaban and rivaroxaban in patients with cerebral venous thrombosis
Cerebral venous thrombosis (CVT) affects approximately 15 people per million annually and represents 0.5% of all stroke [1,2]. Initiation of anticoagulation with heparin followed by warfarin is currently the standard of care, after confirmation of diagnosis with computed tomography (CT) or magnetic resonance (MR) venography [3]. Apixaban and rivaroxaban have been shown to be non-inferior to warfarin for the treatment of deep vein thrombosis and pulmonary embolism [4,5]. However, only case reports and small case series have described their use in patients with CVT.
Source: Thrombosis Research - November 20, 2018 Category: Hematology Authors: Fahrettin Covut, Tariq Kewan, Oscar Perez, Monica Flores, Abdo Haddad, Hamed Daw Tags: Letter to the Editors-in-Chief Source Type: research
Gut microbiota-dependent trimethylamine-N-oxide (TMAO) shows a U-shaped association with mortality but not with recurrent venous thromboembolism
Gut microbiota-dependent trimethylamine-N-oxide (TMAO) correlates with arterial thrombotic events including myocardial infarction and stroke, and mortality. However, the association of TMAO with recurrent venous thromboembolism (VTE) and mortality remains unknown.
Source: Thrombosis Research - December 7, 2018 Category: Hematology Authors: Martin F. Reiner, Daniel M üller, Sara Gobbato, Odile Stalder, Andreas Limacher, Nicole R. Bonetti, Lisa Pasterk, Marie Méan, Nicolas Rodondi, Drahomir Aujesky, Anne Angelillo-Scherrer, Christian M. Matter, Thomas F. Lüscher, Giovanni G. Camici, Arnold Tags: Full Length Article Source Type: research
Neutrophil extracellular traps in thrombi retrieved during interventional treatment of ischemic arterial diseases
The ultrastructure and cellular composition of thrombi has a profound effect on the outcome of acute ischemic stroke (AIS), coronary (CAD) and peripheral artery disease (PAD). Activated neutrophils release a web-like structure composed mainly of DNA and citrullinated histones, called neutrophil extracellular traps (NET) that modify the stability and lysability of fibrin. Here, we investigated the NET-related structural features of thrombi retrieved from different arterial localizations and their interrelations with routinely available clinical data.
Source: Thrombosis Research - January 15, 2019 Category: Hematology Authors: Ádám Z. Farkas, Veronika J. Farkas, István Gubucz, László Szabó, Krisztián Bálint, Kiril Tenekedjiev, Anikó I. Nagy, Péter Sótonyi, László Hidi, Zoltán Nagy, István Szikora, Béla Merkely, Krasimir Kolev Tags: Full Length Article Source Type: research
Bugs in the system
Bugs play a large role in our life. Bugs can be either good, or bad for us. Microorganisms, such as gut microbiota, are usually beneficial to us. They provide a barrier to pathogenic organisms and help to digest our food. However, microbiota also produce Trimethylamine-N-oxide (TMAO), a metabolite of dietary phosphatidylcholine and L-carnitine, that has been recently been shown to increase the risk of arterial thrombotic events, such as myocardial infarction and stroke. In this issue of Thrombosis Research, Reiner and colleagues have investigated whether plasma levels of TMAO also associate with recurrent venous thromboemb...
Source: Thrombosis Research - January 30, 2019 Category: Hematology Authors: Henri H. Versteeg, Marc Rodger Source Type: research
Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide
Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.
Source: Thrombosis Research - February 12, 2019 Category: Hematology Authors: Jon Mabley, Jignesh P. Patel, Abdelrahman Sayed, Roopen Arya, Greg Scutt Tags: Letter to the Editors-in-Chief Source Type: research
The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis
Factor (F) Xa inhibitors are safe and effective alternatives to warfarin in the treatment of venous thrombosis and as stroke prophylaxis in patients with non-valvular atrial fibrillation. Even though the risk of major bleeding is lower for FXa inhibitors than warfarin in general, FXa inhibitors have been reported to cause a different bleeding profile. Inhibition of FXa by rivaroxaban is associated with more gastrointestinal bleeds and heavy uterine bleedings [1 –3] than warfarin. Also, low-dose rivaroxaban has been shown to reduce major ischemic outcomes and death after acute coronary events [4].
Source: Thrombosis Research - March 12, 2019 Category: Hematology Authors: Nina Haagenrud Schultz, P ål Andre Holme, Carola Elisabeth Henriksson, Marie-Christine Mowinckel, Per Morten Sandset, Vibeke Bratseth, Eva-Marie Jacobsen Tags: Letter to the Editors-in-Chief Source Type: research
Non-invasive imaging techniques for the differentiation of acute and chronic thrombosis
Thrombosis is the localized clotting of blood that can occur in both the arterial and venous circulation. It is a key factor in the pathogenesis of acute coronary syndrome, myocardial infarction and stroke and the primary cause of deep vein thrombosis and pulmonary embolism. Rapid and accurate diagnosis of thrombotic episodes is crucial in reducing the morbidity and potential mortality associated with arterial and venous thrombotic disorders by allowing early targeted therapeutic interventions. From a clinical perspective the ability to accurately assess the age and composition of thrombus is highly desirable given that an...
Source: Thrombosis Research - March 13, 2019 Category: Hematology Authors: Nur Nazifah Mohd Yusof, Andrew McCann, Peter J. Little, Hang T. Ta Tags: Review Article Source Type: research
Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey
Oral anticoagulation (OAC) is superior to antiplatelet therapy to prevent stroke in patients with atrial fibrillation (AF). In contrast, patients who have experienced an acute coronary event and/or coronary stent placement benefit from antiplatelet therapy to prevent future adverse cardiac events. While both of these cardiac conditions are highly prevalent on their own, they also frequently occur concurrently. In these situations, combined antiplatelet therapy and OAC significantly increases the risk of bleeding events [1,2].
Source: Thrombosis Research - May 26, 2019 Category: Hematology Authors: David Kopin, W. Schuyler Jones, Andrew Klein, Geoffrey D. Barnes Tags: Letter to the Editors-in-Chief Source Type: research
